Literature DB >> 9101213

Use of urinary beta-2-microglobulin to predict severe renal damage in fetal obstructive uropathy.

A L Freedman1, T P Bukowski, C A Smith, M I Evans, S M Berry, R Gonzalez, M P Johnson.   

Abstract

PURPOSE: Establish a clinically relevant threshold for urinary beta 2-microglobulin (beta 2m) to predict the presence of several renal damage in fetuses with obstructive uropathies.
METHODS: Retrospective review was conducted of urinary beta 2m levels, clinical outcomes, and pathological findings in 36 fetuses evaluated for presumed obstructive uropathy. Patients were divided into those free of renal injury (group 1, n = 13) and those with clinical or pathological evidence of severe irreversible renal injury (group 2, n = 23).
RESULTS: Including all patients, a threshold beta 2m value of > 6 was able to predict the presence of severe renal damage with a 83% sensitivity and 71% specificity. beta 2m levels tended to decrease with increasing gestational age among those patients without renal injury (group 1), while beta 2m levels increased among those with severe renal damage (group 2). There was no difference in mean beta 2m levels in those < 20 weeks (p = 0.065) while there was a high degree of difference in those > 20 weeks of gestation (p < 0.001). In those > 20 weeks, a threshold of > 10 predicted the presence of severe renal damage with 100% sensitivity and specificity.
CONCLUSIONS: Urinary beta 2m, especially in the fetus > 20 weeks, may be a clinically useful marker to detect the presence of severe renal damage due to obstructive uropathy and thus be an important adjuvant in the proper selection of fetuses for antenatal intervention.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101213     DOI: 10.1159/000264415

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  2 in total

1.  First-year profile of biomarkers for early detection of renal injury in infants with congenital urinary tract obstruction.

Authors:  Dusan Kostic; Glenda Priscila Neves Dos Santos Beozzo; Saulo Brasil do Couto; André Henrique Teruaki Kato; Laila Lima; Patricia Palmeira; Vera Lúcia Jornada Krebs; Victor Bunduki; Rossana Pulcineli Vieira Francisco; Marcelo Zugaib; Werther Brunow de Carvalho; Vera Hermina Kalika Koch
Journal:  Pediatr Nephrol       Date:  2019-01-29       Impact factor: 3.714

2.  Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial.

Authors:  Rachel K Morris; Gemma L Malin; Elisabeth Quinlan-Jones; Lee J Middleton; Karla Hemming; Danielle Burke; Jane P Daniels; Khalid S Khan; Jon Deeks; Mark D Kilby
Journal:  Lancet       Date:  2013-08-14       Impact factor: 79.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.